Form 4 Immunic Inc For: 7 July
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Immunic Inc (IMUX)
Immunic Inc stock price live, this page displays NASDAQ IMUX stock exchange data. View the IMUX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Immunic Inc real time stock price chart below.
What Is the Immunic Inc Stock Price Today?
The Immunic Inc stock price today is 12.810.
What Is the Stock Symbol for Immunic Inc?
The stock symbol for Immunic Inc is "IMUX."
What Stock Exchange Does Immunic Inc Trade On?
Immunic Inc is listed and trades on the NASDAQ stock exchange.
Is Immunic Inc a Good Stock to Buy?
Determining whether Immunic Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IMUX quote. (ISIN: US4525EP2001)
What Is the Immunic Inc Stock Price Today?
The Immunic Inc stock price today is 12.810.
What Is the Stock Symbol for Immunic Inc?
The stock symbol for Immunic Inc is "IMUX."
What Stock Exchange Does Immunic Inc Trade On?
Immunic Inc is listed and trades on the NASDAQ stock exchange.
Is Immunic Inc a Good Stock to Buy?
Determining whether Immunic Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IMUX quote. (ISIN: US4525EP2001)
12.810
-1.000(-7.24%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
12.727
13.795
52 wk Range
0.584
15.840
Earnings results expected in 9 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
12.72713.795
52 wk Range
0.58415.840
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
IMUX Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
43.222
Upside
+237.41%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Form 4 Immunic Inc For: 29 June- Investing.com
Immunic appoints Erik Lundgren as new CEO- Investing.com
- Form 4 Immunic Inc For: 7 July
- Investing.com
- Form 4 Immunic Inc For: 29 June
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
10 Buy
0 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 43.222
(+237.41% Upside)
Earnings
Latest Release
May 13, 2026
EPS / Forecast
-1.08 / -0.08
Revenue / Forecast
-- / --
Compare IMUX to Peers and Sector
Metrics to compare | IMUX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIMUXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.8x | −5.1x | −0.4x | |
PEG Ratio | −0.04 | 0.01 | 0.00 | |
Price/Book | 1.2x | 1.6x | 2.6x | |
Price / LTM Sales | - | 10.8x | 2.9x | |
Upside (Analyst Target) | 95.5% | 203.7% | 56.8% | |
Fair Value Upside | Unlock | −8.4% | 8.9% | Unlock |
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Immunic (IMUX) Stock Price Today?
The Immunic stock price today is 12.810 USD.
What Stock Exchange Does Immunic Trade On?
Immunic is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Immunic?
The stock symbol for Immunic is "IMUX."
What Is the Immunic Market Cap?
As of today, Immunic market cap is 175.310M USD.
What Is Immunic's Earnings Per Share (TTM)?
The Immunic EPS (TTM) is -5.070.
When Is the Next Immunic Earnings Date?
Immunic will release its next earnings report on Aug 06, 2026.
From a Technical Analysis Perspective, Is IMUX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Immunic Stock Split?
Immunic has split 2 times.
How Many Employees Does Immunic Have?
Immunic has 95 employees.
What is the current trading status of Immunic (IMUX)?
As of Jul 28, 2026, Immunic (IMUX) is trading at a price of 12.810 USD, with a previous close of 13.810 USD. The stock has fluctuated within a day range of 12.727 USD to 13.795 USD, while its 52-week range spans from 0.584 USD to 15.840 USD.
What Is Immunic (IMUX) Price Target According to Analysts?
The average 12-month price target for Immunic is 43.222 USD, with a high estimate of 85 USD and a low estimate of 19 USD. 10 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +237.41% Upside potential.
What Is the IMUX Premarket Price?
IMUX's last pre-market stock price is 13.580 USD. The pre-market share volume is 210.000, and the stock has decreased by -0.230, or -1.670%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.